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Synthesis and biological evaluation of -tubulin-binding pironetin analogues with 
enhanced lipophilicity 
Miguel Carda,*[a] Juan Murga,[a] Eva Falomir,[a] Santiago Díaz-Oltra,[a] Jorge García-Pla,[a] 
Julián Paños,[a] Chiara Trigili,[b] J. Fernando Díaz,*[b] Isabel Barasoain,*[b] and J. Alberto 
Marco*[c] 
Keywords: Tubulin / Microtubules / Microtubule-disrupting Compounds / Cytotoxicity / Lipophilic Pironetin Analogues 
The preparation of four new lipophilic analogues of the natural
pyrone pironetin is described. The nine-carbon side chain of the 
latter has been replaced in one analogue by a 4-phenylbutyl chain
and in the other three analogues by long aliphatic chains of thirteen
and sixteen carbons, all of them bearing two stereogenic centers.
Their cytotoxic activity and their interactions with tubulin have
been investigated. It has been found that all four are cytotoxic
towards two either sensitive or resistant tumoral cell lines with 
similar IC50 values in each case, thus indicating that, like the parent
natural compound, they also display a covalent mechanism of
action. However, one of them operates in all likelihood through a
mechanism very similar to pironetin whereas the other three seem 
to be cytotoxic via a different mechanism. 
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Introduction 
Microtubules are dynamic polymers which play a central role in 
a number of cellular processes, most particularly cell division, as 
they are key constituents of the mitotic spindle.1 Their shape can 
be described as hollow tubes of about 25 nm external diameter 
constituted of a protein named tubulin. The functional form of this 
protein is a heterodimer formed in turn through non-covalent 
binding of two monomeric constituents. These are two structurally 
related polypeptides of about 450 amino acid residues which are 
called - and -tubulin.2 For cell division to occur in a normal 
way, microtubules must be in a constant state of formation and 
disruption, a process named microtubule dynamics in which GTP 
hydrolysis into GDP plays a key role.3 
It is easy to understand that any molecule which exerts some 
type of action on microtubule dynamics will be able to influence 
the cell division process, not only of normal cells but also of 
tumoral ones. Since such an influence may be exerted by molecules 
that bind to any of the tubulin components, it is not surprising that 
tubulin-binding molecules (TBMs) constitute a very important 
class of anticancer agents.4 TBMs are able to interfere with 
microtubule assembly and functions, either by causing disruption 
of the microtubules or else through their stabilization. In both cases, 
this results in mitotic arrest of eukaryotic cells and subsequent cell 
death. Most of the hitherto described active drugs are natural 
products or derivatives thereof.5 Major drugs can already be found 
on the market and many other promising compounds are in clinical 
trials.4,5 
TBMs may be divided in two broad categories, those that bind to 
-tubulin and those that bind to -tubulin. The latter group is 
presently by far the most numerous and contains products which 
cause either disruption or stabilization of microtubules. Among the 
drugs that belong to this group, the well-known colchicine6 exerts 
its effects by causing disruption of microtubules. In contrast, 
another renowned representative of the same group, paclitaxel, was 
the first-described tubulin-interacting drug with the ability to 
stabilize microtubules.7 Despite the fact that they exert opposite 
effects on the mitotic spindle, both drugs are known to bind to -
tubulin, even though to different sites within that protein subunit. 
The mechanisms of action8 of many of these TBMs and the 
molecular aspects9 of their interactions with tubulin have been 
studied using a broad palette of methods.10 
The number of products reported to bind to -tubulin is very 
small, the naturally occurring 5,6-dihydro--pyrone pironetin (Fig. 
1) being the first example,11 followed a short time later by the 
peptide-like hemiasterlin family.12 Pironetin proved a potent 
inhibitor of tubulin assembly and was found to arrest cell cycle 
progression in the G2/M phase.13 This feature has motivated a 
number of groups to undertake total syntheses of this natural 
compound.14 Some synthetic and biological studies on modified 
variants of pironetin have previously been published.15 
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Insert Figure 1 here 
Some structure-activity (SAR) studies on pironetin have been 
reported.13 These studies have shown that the presence of the 
conjugated C2C3 double bond and of the hydroxyl group at C-9, 
either free or methylated, are essential for the biological activity. 
The presence of a (7R)-hydroxyl group also seems to be very 
relevant.13c The epoxidation of the C12-C13 double bond has been 
shown to cause a decrease in the activity13a,b but this may perhaps 
involve a deleterious effect of the oxirane ring, rather than a strict 
need of this C=C bond. No data are available about the importance 
of the remaining structural features.15 It has been proposed that 
the Lys352 residue of the -tubulin chain adds in a Michael 
fashion to the conjugated double bond of pironetin, therefore 
forming a covalent bond with C-3 of the pyrone ring (Fig. 2). In 
addition, it has been suggested that the Asn258 residue of -
tubulin holds the pironetin molecule through two hydrogen bonds 
to the pyrone carbonyl and the methoxyl oxygen atoms.13 
Insert Figure 2 here 
The appearance of resistances to existing drugs has led to a 
continuous need of developing new bioactive compounds that 
overcome such problems. Even though first observed in the case of 
antibiotics, resistances have also been reported to TBM.4c,e,h,16 
The investigation of new members of this compound class 
therefore constitutes an important goal in chemistry and 
pharmacology. As a member of the up to now small group of 
products that bind to -tubulin, pironetin constitutes a 
pharmacologically interesting target. Thus, the purpose of our 
present research is the preparation of pironetin analogues that 
retain a substantial proportion of the biological activity of the 
natural metabolite while displaying a more simplified structure. 
Indeed, pironetin is not an extremely complex molecule but, with 
six sp3 stereocenters, a total synthesis will be anyway lengthy 
enough as to make not very practical a preparation at large scale. 
Our investigation aims at establishing which elements of the 
pironetin molecule are essential for its activity and, desirably, at 
achieving an improvement of the latter. 
In order to develop SAR studies based upon the pironetin 
framework, we started considering a simplified model structure 
where all elements that have not yet proven to be essential were 
removed. The elements that were maintained are the conjugated 
pyrone ring and the side chain with the methoxy group at C-9. The 
hydroxyl group at C-7 was removed in some substrates and 
retained in others, in order to see its influence on the activity. All 
alkyl pendants (methyls at C-8 and C-10, ethyl at C-4) and the 
isolated C12−C13 double bond were removed. The configurations 
of the three remaining stereocenters were varied in a systematic 
way. Accordingly, the selected target structures are schematically 
shown in Figure 3. All four possible stereoisomers with general 
constitution 1, where no hydroxyl group at C-7 is present, were 
prepared. Furthermore, all eight stereoisomers with constitution 2, 
with a hydroxyl group at C-7, were synthesized.17 
Insert Figure 3 here 
The cytotoxic activity of these analogues and their interactions 
with tubulin were subsequently investigated. For the measurement 
of the cytotoxic activity, the ovarian carcinoma cells sensitive 
(A2780) and resistant (A2780AD) to chemotherapy by P-
glycoprotein overexpression were used.17 It was found on one 
hand that the analogues were cytotoxic in the low micromolar 
range, thus about three orders of magnitude less active than the 
parent molecule.17 On the other hand, they behaved in the same 
way as pironetin in that they killed both resistant and non resistant 
cells with a similar IC50, as expected for compounds with a 
covalent mechanism of action.13 The general conclusion was that 
the synthetic pironetin analogues share the mechanism of action of 
the natural compound and compete for the same binding site to -
tubulin, leading to disruption of the microtubule network. It is 
worth mentioning that variations in the configurations of the three 
stereocenters (C-5, C-7, C-9) did not translate into significant 
differences in the biological activity.17 
In continuation of our efforts in this line of research, we have 
now investigated the influence of the nature of the lipophilic side 
chain attached to the dihydropyrone ring. Indeed, we intend to 
prepare tubulin-active molecules with a hybrid structure and the 
ability to bind to two different points in the tubulin network. Since 
one half of these hybrid molecules will be pironetin-like, we wish 
to acquire knowledge about the nature and size of the required 
spacer fragment. Accordingly, the four pironetin analogues 3-6 
were prepared (Fig. 4). As regards the stereocenters, and in view of 
the aforementioned fact that their configurations do not seem to 
play a significant role in the biological activity, compounds 3-6 
were prepared with the same configuration as natural pironetin at 
C-5, C-7 and C-9. The difference with the previously reported 
analogues 1-2 resides in the lipophilic end of the side chain, which 
is much longer in 3 and 4. Compound 5 is an O-methylated 
analogue of 4 whereas compound 6 contains a phenyl ring instead 
of the aliphatic chain. 
Insert Figure 4 here 
Results and Discussion 
Chemical results 
Dihydropyrones 3-6 were prepared using the methodology 
employed in the case of compounds of general structure 2.17 
Scheme 1 depicts the details of the synthetic sequence for the case 
of pyrone 3, where n-decanal was the starting material. 
Insert Scheme 1 here 
Brown’s asymmetric allylation of n-decanal using a chiral 
allylborane afforded homoallyl alcohol 7. The required borane was 
prepared through reaction of allylmagnesium bromide with the 
commercially available ()-diisopinocampheylboron chloride, ()-
Ipc2BCl.18 Methylation of the free hydroxyl group of compound 7 
yielded methyl ether 8. Ozonolytic cleavage of the olefinic bond in 
8 gave the intermediate aldehyde 9, which was not isolated but 
directly subjected to asymmetric allylation, this time using the 
chiral allylborane formed from allylmagnesium bromide and (+)-
Ipc2BCl. This gave rise to homoallyl alcohol 10 as an inseparable 
mixture of diastereoisomers in a 88:12 ratio. Silylation of this 
mixture gave 11, which was subjected to ozonolytic cleavage of the 
C=C bond. Without purification, the intermediate aldehyde 12 was 
submitted to asymmetric allylation with the chiral allylborane 
generated from ()-Ipc2BCl and allylmagnesium bromide. This 
provided homoallylic alcohol 13 as a single diastereoisomer, the 
minor stereoisomer being removed during the chromatographic 
separation. Reaction of 13 with acryloyl chloride at low 
temperature gave acrylate 14, which was then subjected to ring-
closing metathesis19 in the presence of Grubbs first-generation 
catalyst Ru-I. This afforded the corresponding dihydropyrone 
which, after acid-catalyzed desylilation, yielded pironetin analogue 
3. 
An analogous reaction sequence starting from n-tridecanal 
served to prepare dihydropyrones 4 and 5, whereas benzaldehyde 
was used for the synthesis of 6. The complete details of these 
syntheses are given in the Supporting Information. 
 3
Biological results 
Cellular effects of the compounds. We have determined the IC50 
values for analogues 3-6 and compared them with that of pironetin 
on A2780 and A2780AD human ovary carcinomas (Table 1). 
Pironetin proved active in both the parental and the resistant cell 
lines, as expected for a compound with a covalent mechanism of 
action.20 While about three orders of magnitude less active than 
pironetin, analogues 3-6 have also been found cytotoxic towards 
A2780 and A2780AD cells and are able to kill both resistant and 
non resistant cells with similar IC50 values. As commented above, 
this is what should be expected for compounds with a covalent 
mechanism of action. 
In order to study the effect of compounds 3-6 on the microtubule 
cytoskeleton, we incubated cells in the presence of these ligands 
for 24 hours (Fig. 5). Pironetin at 50 nM concentration completely 
depleted cytoplasmic microtubules (C,D and inset): cells are 
arrested in the prometaphase13a,b and type III mitotic spindles are 
observed,21 with the chromosomes being arranged in a ball of 
condensed DNA enclosing one or more star-shaped aggregates of 
microtubules. 
With 100 µM 3, 25 µM 4 and 15 µM 5, disorganization and 
some depolymerization of the microtubule cytoskeleton are 
observed: the cells get rounded and detach from the plastic 
substrate were they are growing, with shrinking of the cell nucleus 
occurring in some cases (Fig. 5, E-J). No mitotic cells are observed 
in these cell preparations. However, ligand 6 at 200 µM is found to 
cause microtubule depolymerization and cell arrest at the 
prometaphase, as in the case of pironetin (see Fig. 5, K,L and inset). 
We next studied whether ligands 3-6 were capable of blocking 
cells in the G2/M phase of the cell cycle of A549, as other 
microtubule modulating agents do. We incubated these cells for 20 
hours in the presence of the different ligands (3-6) or the drug 
vehicle (Fig. 6). Pironetin at 50 nM concentration almost 
completely arrested cells in the G2/M phase and, interestingly, so 
did 200 M 6. In contrast, ligands 3 (100 M), 4 (50 M), and 5 
(10 M) only caused a decrease in the number of G2/M cells with 
appearance of subG1 cells, presumably dying cells. These results 
indicate that, although markedly less active, compound 6 is the 
only ligand that behaves like pironetin. In addition, the results 
further indicate that compounds 3-5, while being active against the 
tubulin cytoskeleton, may exert their cytotoxicity through an 
alternative pathway. 
Tubulin assembly. The critical concentration of tubulin required 
for assembly was determined in GAB in the presence of a large 
excess (100 M) of compounds 3-6 (Table 2). As shown in the 
Table, the concentration of tubulin required to produce assembly 
(critical concentration22) oscillate between 3.3 M in the absence 
of ligands and 4.9 M in the presence of 5, the most active of these 
compounds as regards this property. The observed increase of the 
critical concentration required indicates that, as expected for a 
pironetin analogue, compounds 3-6 are also able to inhibit the 
assembly of tubulin. 
Summary 
Four new pironetin derivatives 3-6 with an extended lypophilic 
side chain were synthesized with the aim at exploring the influence 
of the side chain in their biological activity. All the compounds are 
cytotoxic in the micromolar range against both non-resistant and 
resistant p-glycoprotein overexpressing, multidrug ovarian 
carcinoma cell lines, similar IC50 values being found in both cell 
lines. However, although all the aforementioned compounds are 
able to inhibit microtubule assembly, both in vitro and in cell 
cultures, thus sharing the general mechanism of action of tubulin 
assembly inhibition, compounds 3-5 containing a long aliphatic 
side chain differ from pironetin and compound 6 in that they do not 
accumulate cells in the G2/M phase of the cell cycle. This indicates 
that, in contrast to pironetin and 6, compounds 3-5 trigger an 
alternative mechanism for cytotoxicity which leads to cell death. 
Experimental Section 
Chemical procedures 
General experimental procedures: 1H/13C NMR spectra were measured at 
500/125 MHz in CDCl3 solution at 25 C. The signals of the deuterated 
solvent (CDCl3) were taken as the reference (the singlet at  7.25 for 1H 
NMR and the triplet centered at 77.00 ppm for 13C NMR data). Carbon 
atom types (C, CH, CH2, CH3) were determined with the DEPT pulse 
sequence. High resolution mass spectra were run by the electrospray mode 
(ESMS). IR data are given only for compounds with significant functions 
(OH, C=O) and were recorded as oily films on NaCl plates (oils) or as KBr 
pellets (solids). Optical rotations were measured at 25°C. Reactions which 
required an inert atmosphere were carried out under N2 with flame-dried 
glassware. Et2O and THF were freshly distilled from sodium/benzophenone 
ketyl and transferred via syringe. Dichloromethane was freshly distilled 
from CaH2. Tertiary amines were freshly distilled from KOH. Toluene was 
freshly distilled from sodium wire. Commercially available reagents were 
used as received. Unless detailed otherwise, "work-up" means pouring the 
reaction mixture into brine, followed by extraction with the solvent 
indicated in parenthesis. If the reaction medium was acidic, an additional 
washing with 5% aq NaHCO3 was performed. If the reaction medium was 
basic, an additional washing with aq NH4Cl was performed. New washing 
with brine, drying over anhydrous Na2SO4 and elimination of the solvent 
under reduced pressure were followed by chromatography on a silica gel 
column (60-200 m) and elution with the indicated solvent mixture. Where 
solutions were filtered through a Celite pad, the pad was additionally 
washed with the same solvent used, and the washings incorporated to the 
main organic layer. 
 
(R)-Tridec-1-en-4-ol (7). Allylmagnesium bromide (commercial 1M 
solution in Et2O, 15 mL, 15 mmol) was added dropwise under N2 via 
syringe to a cooled solution of (+)-Ipc2BCl (5.77 g, ~ 18 mmol) in dry Et2O 
(75 mL) (dry ice-acetone bath). After finishing the addition, the dry ice-
acetone bath was replaced by an ice bath, and the mixture was stirred for 1 
h. The solution was allowed to stand, whereby precipitation of magnesium 
chloride took place. The supernatant solution was carefully transferred to 
another flask via canula. After cooling this flask at 90 C, a solution of n-
decanal (2.25 mL, 1.87 g, 12 mmol) in dry Et2O (35 mL) was added 
dropwise via syringe. The resulting solution was further stirred at 90 C 
for 2 h. The reaction mixture was quenched through addition of phosphate 
pH 7 buffer solution (15 mL), MeOH (15 mL) and 30% H2O2 (7 mL). After 
stirring for 30 min., the mixture was poured onto satd. aq NaHCO3 and 
worked up (extraction with Et2O). The residue was subjected to a careful 
column chromatography on silica gel (hexanes, then hexanes-EtOAc, 9:1) 
to afford 7 (2.26 mg, 95%): oil; []D +3.3 (c 1.1; CHCl3). Physical and 
spectral data as reported.23 The enantiomeric ratio was found to be 96:4 by 
means of chiral HPLC using a Kromasil 5-AmyCoat column (4.6 x 20 mm). 
Elution was performed with a hexane/isopropanol 99:1 mixture, and a flux 
of 0.4 mL/min. Elution times of both enantiomers: 21.21 (S) and 22.87 min 
(R). 
 
(R)-4-Methoxytridec-1-ene (8). Sodium hydride (60% slurry in mineral oil, 
amount equivalent to 20 mmol) was washed two times under N2 with dry 
hexane and once with dry THF. Then, THF (75 mL) was added and the 
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suspension was cooled in an ice bath. Alcohol 7 (1.98 g, 10 mmol) was then 
dissolved in dry THF (25 mL) and added dropwise to the sodium hydride 
suspension. The mixture was then allowed to reach room temperature. 
Subsequently, methyl iodide (1.87 mL, ca. 30 mmol) was added in one 
portion and the mixture was stirred overnight at room temp. Work-up 
(Et2O) was followed by column chromatography on silica gel (hexanes-
EtOAc, 19:1) to afford 8 (1.95 g, 92%): oil; []D +2.9 (c 0.1; CHCl3); IR 
and 1H NMR data as reported24; 13C NMR (125 MHz)  135.1, 80.6 (CH), 
116.7, 37.8, 33.4, 31.9, 29.8, 29.7, 29.6, 29.4, 25.3, 22.7 (CH2), 56.5, 14.1 
(CH3). 
 
(4R,6R)-6-Methoxypentadec-1-en-4-ol (10). Olefin 8 (1.275 g, ca. 6 
mmol) was dissolved in CH2Cl2 (100 mL) and cooled to 78 ºC. A stream 
of ozone-containing air was then bubbled through the solution until 
complete consumption of the starting material (TLC monitoring). Ozone 
residues were then eliminated by bubbling a stream of N2, and the mixture 
was allowed to reach room temperature, treated with PPh3 (3.15 g, ~ 12 
mmol) and allowed to stir for 2 hours. After solvent removal under reduced 
pressure, the crude residue was stirred for 10 min. under cold pentane (40 
mL) and filtered. The solution was then concentrated under reduced 
pressure and the crude residue containing 9 was used directly in the next 
step. 
Allylmagnesium bromide (commercial 1M solution in Et2O, 8 mL, 8 mmol) 
was added dropwise under N2 via syringe to a cooled solution of (+)-
Ipc2BCl (3.2 g, ~ 10 mmol) in dry Et2O (50 mL) (dry ice-acetone bath). 
After finishing the addition, the dry ice-acetone bath was replaced by an ice 
bath, and the mixture was stirred for 1 h. The solution was allowed to stand, 
whereby precipitation of magnesium chloride took place. The supernatant 
solution was carefully transferred to another flask via canula. After cooling 
this flask at 90 C, a solution of the crude aldehyde 9 from above in dry 
Et2O (15 mL) was added dropwise via syringe. The resulting solution was 
further stirred at 90 C for 2 h. The reaction mixture was quenched 
through addition of phosphate pH 7 buffer solution (40 mL), MeOH (40 
mL) and 30% H2O2 (20 mL). After stirring for 30 min., the mixture was 
poured onto satd. aq NaHCO3 and worked up (extraction with Et2O). The 
residue was subjected to a careful column chromatography on silica gel 
(hexanes, then hexanes-EtOAc, 19:1) to afford 10 (1.077 g, 70% overall 
from 8) as an 88:12 mixture of diastereoisomers which were very difficult 
to separate and was used as such in the next step. For analytical purposes, 
an aliquot could be concentrated to about 95% purity by means of careful 
column chromatography: oil; []D 22.8 (c 0.8; CHCl3); 1H NMR (500 
MHz)  ddt, J = 17, 10, 7 Hz), 5.15-5.05 (2H, br m), 3.95 (1H, 
m), 3.48 (1H, m), 3.37 (3H, s), 2.90 (1H, br s, OH), 2.25 (2H, m), 1.70-1.40 
(4H, br m), 1.35-1.25 (14H, br m), 0.89 (3H, t, J = 7 Hz); 13C NMR (125 
MHz)  135.0, 79.3, 68.0 (CH), 117.5, 42.3, 39.0, 33.1, 31.9, 29.8, 29.6, 
29.5, 29.3, 25.4, 22.7 (CH2), 56.7, 14.1 (CH3). HR ESMS m/z (% rel. int.) 
279.2302 (M+Na+). Calcd. for C16H32NaO2, 279.2300. 
 
(4R,6R)-4-(Tert-butyldimethylsilyloxy)-6-methoxypentadec-1-ene (11). 
Alcohol 10 (1.025 g, 4 mmol) was dissolved under N2 in dry CH2Cl2 (20 
mL) and treated sequentially with 2,6-lutidine (700 L, 6 mmol) and 
TBSOTf (1.15 mL, 5 mmol). The reaction mixture was then stirred for 1 h 
at room temp. and worked up (extraction with CH2Cl2). Column 
chromatography on silica gel (hexanes-EtOAc, 19:1) afforded 11 (1.33 g, 
90%) as an 88:12 mixture of diastereoisomers which were very difficult to 
separate and was used as such in the next step. For analytical purposes, an 
aliquot could be concentrated to about 95% purity by means of careful 
column chromatography: oil; []D 8.2 (c 0.1; CHCl3); 1H NMR (500 
MHz)  ddt, J = 17, 10, 7 Hz), 5.10-5.00 (2H, br m), 3.93 (1H, 
m), 3.34 (1H, m), 3.30 (3H, s), 2.24 (2H, m), 1.60-1.40 (4H, br m), 1.35-
1.25 (14H, br m), 0.90 (12H, strong singlet of 9H overlapping a methyl 
triplet at 0.89 ppm), 0.08 (6H, s); 13C NMR (125 MHz)  18.1 (C), 134.9, 
77.1, 68.6 (CH), 117.0, 42.8, 41.7, 33.0, 31.9, 29.9, 29.7, 29.6, 29.3, 24.8, 
22.7 (CH2), 55.7, 26.0 (x 3), 14.1, 4.1, 4.7 (CH3). HR ESMS m/z (% rel. 
int.) 393.3162 (M+Na+). Calcd. for C22H46NaO2Si, 393.3165 . 
 
(4S,6R,8R)-6-(Tert-butyldimethylsilyloxy)-8-methoxyheptadec-1-en-4-ol 
(13). Prepared in two steps from 11 (via the non isolated aldehyde 12) in 
47% overall yield according to the same experimental conditions as in the 8 
 10 step. Careful chromatography on silica gel (hexane-Et2O, 9:1, then 
8:2) permitted the isolation of 13 as a diastereomerically pure compound 
(by NMR): oil; []D 4.1 (c 0.1; CHCl3); IR max 3400 (br, OH) cm-1; 1H 
NMR (500 MHz)   ddt, J = 17, 10, 7 Hz), 5.15-5.05 (2H, br m), 
4.18 (1H, m), 4.05 (1H, m), 3.50 (1H, br s, OH), 3.29 (3H, s), 3.26 (1H, m), 
2.30-2.10 (2H, br m), 1.70-1.50 (4H, br m), 1.35-1.25 (16H, br m), 0.90 
(12H, strong singlet of 9H overlapping a methyl triplet at 0.89 ppm), 0.12 
(3H, s), 0.10 (3H, s); 13C NMR (125 MHz)  17.9 (C), 135.0, 77.3, 69.3, 
68.1 (CH), 117.0, 42.4, 42.1, 41.0, 32.8, 31.9, 29.9, 29.7, 29.6, 29.3, 24.7, 
22.7 (CH2), 55.6, 25.9 (x 3), 14.1, 4.4, 4.9 (CH3). 
 
(4S,6S,8R)-6-(Tert-butyldimethylsilyloxy)-8-methoxyheptadec-1-en-4-yl 
acrylate (14). Compound 13 (415 mg, ca. 1 mmol) was dissolved under N2 
in dry CH2Cl2 (30 mL), cooled to 78 ºC and treated sequentially with N,N-
diisopropyl ethylamine (2.1 mL, 12 mmol) and acryloyl chloride (815 L,  
ca. 10 mmol). The reaction mixture was stirred at –78 ºC until consumption 
of the starting material (about 45 min., TLC monitoring). Work-up 
(extraction with CH2Cl2) and column chromatography on silica gel 
(hexane-Et2O, 9:1) provided 14 (361 mg, 77%): oil; []D +2.2 (c 0.5; 
CHCl3); IR max 1727 (C=O) cm-1; 1H NMR (500 MHz)  6.38 (1H, dd, J = 
17.3, 1.5 Hz), 6.10 (1H, dd, J = 17.3, 10.5 Hz), 5.80 (1H, dd, J = 10.5, 1.5 
Hz), 5.78 (1H, ddt, J = 17, 10.2, 7 Hz), 5.10-5.00 (3H, br m), 3.86 (1H, m), 
3.29 (3H, s), 3.28 (1H, m), 2.40 (2H, m), 1.85-1.40 (6H, br m), 1.35-1.25 
(14H, br m), 0.89 (12H, strong singlet of 9H overlapping a methyl triplet at 
0.89 ppm), 0.05 (3H, s), 0.04 (3H, s); 13C NMR (125 MHz)  165.7, 18.0 
(C), 133.4, 129.0, 77.5, 71.2, 67.0 (CH), 130.2, 118.0, 42.7, 42.0, 39.0, 33.2, 
31.9, 29.9, 29.7, 29.6, 29.3, 24.7, 22.7 (CH2), 55.8, 26.0 (x 3), 14.1, 4.3, 
4.4 (CH3); HR ESMS m/z (% rel. int.) 491.3529 (M+Na+). Calcd. for 
C27H52NaO4Si, 491.3533. 
 
(6S)-6-[(2S,4R)-2-(Tert-butyldimethylsilyloxy)-4-methoxytridecyl]-5,6-
dihydro-2H-pyran-2-one (15). Diolefin 14 (234 mg, ca. 0.5 mmol) was 
dissolved under N2 in dry, degassed CH2Cl2 (50 mL) and treated with 
Grubbs catalyst PhCH=RuCl2(PCy3)2 (41 mg, ca. 0.05 mmol). The mixture 
was heated at reflux until consumption of the starting material (ca. 4 h, TLC 
monitoring). Solvent removal under reduced pressure and column 
chromatography on silica gel (hexane-EtOAc, 19:1) yielded pyranone 15 
(187 mg, 85%): ): oil; D 6.5 (c 0.2, CHCl3); IR max 1732 (C=O) cm-1; 
1H NMR (500 MHz)  6.86 (1H, dt, J = 9.7, 4 Hz), 6.00 (1H, br d, J = 9.7 
Hz), 4.58 (1H, m), 4.06 (1H, m), 3.28 (3H, s), 3.26 (1H, quint, J  6 Hz), 
2.30 (2H, m), 2.00 (1H, m), 1.65-1.55 (3H, br m), 1.55-1.40 (2H, br m), 
1.35-1.20 (14H, br m), 0.87 (12H, strong singlet of 9H overlapping a 
methyl triplet at 0.89 ppm), 0.07 (3H, s), 0.06 (3H, s); 13C NMR (125 MHz) 
 164.2, 18.0 (C), 145.1, 121.5, 77.7, 74.5, 66.3 (CH), 43.3, 43.1, 33.2, 31.9, 
29.9, 29.7, 29.6, 29.5, 29.3, 24.7, 22.6 (CH2), 55.8, 25.9 (x 3), 14.1, 4.4, 
4.5 (CH3); HR ESMS m/z (% rel. int.) 463.3218 (M+Na+). Calcd. for 
C25H48NaO4Si, 463.3219. 
 
(6S)-6-[(2S,4R)-2-Hydroxy-4-methoxytridecyl]-5,6-dihydro-2H-pyran-
2-one (3). Compound 15 (132 mg, 0.3 mmol) was dissolved in MeOH (15 
mL) and treated with PPTS (15 mg, 0.06 mmol) and water (0.15 mL). The 
mixture was then heated at reflux overnight, cooled and neutralized by 
addition of solid NaHCO3. After filtering, the solution was evaporated 
under reduced pressure, and the oily residue was subjected to column 
chromatography on silica gel (hexanes-EtOAc, 1:4). This provided 3 (88 
mg, 90%): oil; D 16 (c 1, CHCl3); IR max 1712 (C=O) cm-1; 1H NMR 
(500 MHz)  6.86 (1H, m), 6.00 (1H, d, J = 9.5 Hz), 4.72 (1H, m), 4.22 (1H, 
 5
m), 3.45 (1H, m), 3.35 (4H, br s, OMe + OH), 2.45-2.30 (2H, br m), 1.90-
1.40 (6H, br m), 1.35-1.20 (14H, br m), 0.87 (3H, t, J = 6.8 Hz); 13C NMR 
(125 MHz)  164.4 (C), 145.2, 121.4, 79.6, 75.1, 64.7 (CH), 42.9, 39.4, 
32.8, 31.9, 30.0, 29.7, 29.6, 29.5, 29.3, 25.5, 22.6 (CH2), 56.6, 14.1 (CH3); 
HR ESMS m/z (% rel. int.) 349.2358 (M+Na+). Calcd. for C19H34NaO4, 
349.2354. 
 
Biological procedures 
Cell culture 
Human A549 non small lung carcinoma cells were cultured in RPMI 
1640 supplemented with 10% FCS, glutamine, and antibiotics as previously 
described.20 Human ovarian carcinomas A2780 and A2780AD (MDR 
overexpressing P-glycoprotein) were cultured as above with the addition of 
0.25 units/mL of bovine insulin. 
Cytotoxicity assays, indirect immunofluorescence and cell 
cycle 
Cytotoxic evaluation was performed with A2780 and A2780AD cells 
with the MTT assay modified as previously described.25 Indirect 
immunofluorescence was performed in A549 cells that had been cultured 
overnight in 12 mm round coverslips and incubated a further 24 hours in 
the absence (drug vehicle DMSO) or in the presence of different ligand 
concentrations. Attached cells were permeabilized with Triton X100 and 
fixed with 3.7% formaldehyde. Microtubules were specifically stained with 
DM1A α-tubulin monoclonal antibodies and DNA with Hoechst 33342 as 
previously described.26 The preparations were examined using a Zeiss 
axioplan epifluorescence microscope and the images were recorded in a 
Hamamatsu 4742-95 cooled CCD camera. Progression through the cell 
cycle analysis was assesed by flow cytometry DNA determination with 
propidium iodide. Cells were fixed, treated with RNase and stained with 
propidium iodide as previously described.[27] Analysis was performed in a 
Coulter Epics XL flow cytometer. 
Tubulin assembly inhibition assay 
The effect of the compounds in the assembly of purified tubulin was 
determined by incubating 20 M purified tubulin at 37 ºC for 30 minutes in 
GAB (glycerol assembling buffer, 3.4 M glycerol, 10 mM sodium phospate, 
1 mM EGTA, 1 mM GTP, 6 mM MgCl2 at pH 6.5) in the presence of 25 
M docetaxel, 100 M of one of the analogs PTA-PF or JPP or 2 L 
DMSO (vehicle). The samples were processed and the critical 
concentration for tubulin assembly22 in the presence of the ligands 
calculated as described.27 
Supporting Information (see footnote on the first page of this article): 
experimental procedures and preparation of pyrones 4, 5 and 6, and of all 
required synthetic intermediates. Graphical 1H and 13C NMR spectra of all 
new compounds. 
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Figure 1. Structures of two natural products reported to selectively bind to 
-tubulin. 
Figure 2. Schematic model of the covalent union of pironetin to its binding 
site at the -tubulin surface. 
Figure 3. General structures of simplified pironetin analogues [17]. 
Figure 4. Structures of new pironetin analogues. 
Figure 5. Effect of compounds 3-6 as compared to the parent molecule 
pironetin on the microtubule network and nucleus morphology of A549 
cells.  Cells were incubated for 24 hours with either drug vehicle DMSO 
( A,B) , 50 nM pironetin (C,D), 100 µM 3 (E,F), 25 µM 4 (G,H), 15 µM 5 
(I,J) and 200 µM 6 (K,L). Microtubules are stained with α-tubulin 
antibodies (A, C, E, G, I, K) whereas DNA ((B,C,F,H,J,L) was stained with 
Hoechst 33342. Insets (A,B,C,D,K,L) are mitotic spindles of the same 
preparation. The scale bar (L) represents 10 µm. All panels and insets have 
the same magnification. 
Figure 6. Cell cycle histogram of A549 lung carcinoma cells untreated and 
treated with pironetin and pironetin analogues of 3-6 .The lowest ligand 
concentration that induces maximal effect on the cell cycle is depicted. 
Scheme 1. Synthesis of pyrones 3-6. (a) ()-Ipc2BCl, allylMgBr, Et2O, 78ºC, 1 h, then addition of n-decanal, 2 h, 78ºC, 95% (e.r. 96:4); (b) 
NaH, THF, 0ºC, then MeI, RT, overnight, 92%; (c) O3, CH2Cl2, 78ºC; (d) 
(+)-Ipc2BCl, allylMgBr, Et2O, 78ºC, 1 h, followed by addition of the 
aldehyde, 2 h, 78ºC (70% overall from 8, d.r. 88:12); (e) TBSOTf, 
CH2Cl2, 2,6-lutidine, RT, 1 h (90%); (f) O3, CH2Cl2, 78ºC, then PPh3; (g) 
()-Ipc2BCl, allylMgBr, Et2O, 78ºC, 1 h, followed by addition of the 
aldehyde, 2 h, 78ºC (47% overall yield from 11, d.r.>95:5); (h) 
CH2=CHCOCl, CH2Cl2, iPr2NEt, 78 ºC, 45 min (77%); (i) (1) 10% cat. 
Ru-I, CH2Cl2, , 4 h (85%); (2) PPTS (cat.), MeOH, , overnight (90%). 
Acronyms and abbreviations: TBS, tert-butyldimethylsilyl; PPTS, 
pyridinium p-toluenesulfonate; Ipc, isopinocampheyl; Tf, trifluoromethane-
sulfonyl. 
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Table 1. Effect of pironetin analogues 3-6 on the growth of A2780 
and A2780AD (MDR overexpressing P-glycoprotein) ovarian 
carcinomas.a 
 
Ligand A2780 (M)b A2780AD (M)b R/Sc 
Pironetin 0.0062 ±0.0012 0.0093 ±0.0014 1.5 
3 39.7 ± 0.5 38.6 ± 1.1 0.97 
4 14.1 ± 0.424 12.5 ± 0.353 0.90 
5 9.2 ± 0.3 10.9 ± 0.05 1.2 
6 54.7 ± 5.4 48 ± 0.7 0.9 
 
a IC50 (50% inhibition of cell proliferation) of the ligands determined in 
ovarian carcinomas. 
b Values mean IC50 as the mean ± standard error of three independent 
experiments. 
c Resistance index (the relative resistance of A2780AD cell line, obtained 
dividing the IC50 of the resistant cell line by that of the parental A2780 cell 
line). 
 
 
 
 
 
 
 
 
Table 2. Critical concentration values of tubulin for ligand-induced 
microtubule assembly induced by tetrahydrofuran derivatives 3-6 
(ligand concentrations are 25 M for docetaxel and 100 M for the 
ligands). 
 
Ligand Cr (M)a 
Control 3.3 ± 0.3 
Docetaxel 1.3 ± 0.4 
3 3.8 ± 0.9 
4 4.3 ± 1.3 
5 4.9 ± 0.8 
6 3.5 ± 0.8 
 
a Cr values are the mean ± standard error of three independent 
experiments. 
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General features. NMR spectra were measured at 25 °C. The signals of the deuterated solvent 
(CDCl3) were taken as the reference. Multiplicity assignments of 13C signals were made by means of 
the DEPT pulse sequence. High resolution mass spectra were run by the electrospray mode (ESMS). IR 
data were measured with oily films on NaCl plates (oils) or KBr pellets (solids) and are given only for 
molecules with relevant functional groups (OH, C=O). Optical rotations were measured at 25 °C. 
Experiments which required an inert atmosphere were carried out under dry N2 in a flame-dried 
glassware. Et2O and THF were freshly distilled from sodium/benzophenone ketyl and transferred via 
syringe. Dichloromethane was freshly distilled from CaH2. Tertiary amines were freshly distilled from 
KOH. Commercially available reagents were used as received. Unless detailed otherwise, "work-up" 
means pouring the reaction mixture into brine, followed by extraction with the solvent indicated in 
parenthesis. If the reaction medium was acidic (basic), an additional washing with 5% aq NaHCO3 (aq 
NH4Cl) was performed. New washing with brine, drying over anhydrous Na2SO4 and elimination of the 
solvent under reduced pressure were followed by chromatography on a silica gel column (60-200 m) 
with the indicated eluent. Where solutions were filtered through a Celite pad, the pad was additionally 
washed with the same solvent used, and the washings incorporated to the main organic layer. 
Acronyms used hereafter: DIP-Cl = diisopinocampheylboron chloride; TBS = t-butyldimethylsilyl; Tf 
= trifluoromethanesulfonyl; PPTS = pyridinium p-toluenesulfonate; DMAP = 4-(N,N-dimethylamino) 
pyridine. 
General reaction conditions (see schemes A-C) 
General procedure for asymmetric allylations (reaction +a). Allylmagnesium bromide (commercial 
1M solution in Et2O, 10 mL, 10 mmol) was added dropwise under N2 via syringe to a solution of (+)-
DIP-Cl (3.85 g, 12 mmol) in dry Et2O (50 mL) cooled at 78C. After replacing the latter by an ice 
bath, the mixture was stirred for 1 h. The solution was then allowed to stand, which caused 
precipitation of magnesium chloride. The supernatant solution was then carefully transferred to another 
flask via canula. After cooling this flask at 78C, a solution of the appropriate aldehyde (8 mmol) in 
dry Et2O (25 mL) was added dropwise via syringe. The resulting solution was further stirred at the 
same temp. for 1 h. The reaction mixture was then quenched through addition of phosphate pH 7 buffer 
solution (50 mL), MeOH (50 mL) and 30% H2O2 (25 mL). After stirring for 30 min., the mixture was 
poured onto satd. aq NaHCO3 and worked up (Et2O). Column chromatography on silica gel (hexanes-
Et2O or hexanes-EtOAc mixtures) afforded the desired homoallylic alcohol. Reaction a is performed 
in the same way except for the use of ()-DIP-Cl. 
General procedure for sequential ozonolysis/asymmetric allylation (reaction +b or b). The 
appropriate olefin (10 mmol) was dissolved in dry CH2Cl2 (100 mL) and cooled to 78C. A stream of 
ozone-oxygen was bubbled through the solution until persistence of the bluish color. Dry N2 was then 
bubbled through the solution for 10 min. at the same temperature. After addition of PPh3 (5.25 g, 20 
mmol), the solution was left to stir at room temp. for 2 h. Solvent removal under reduced pressure gave 
a solid material, which was washed three times with cold pentane (3 x 15 mL). The solid (Ph3PO) was 
discarded, and the organic phase was evaporated under reduced pressure to yield the crude aldehyde as 
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a colorless oil, which was used as such in the asymmetric allylation (for weight calculations, the yield 
of the ozonolysis step was assumed to be quantitative). The overall process is described as +b or b 
according to the use of (+)- or ()-DIP-Cl in the allylation step. 
General procedure for O-methylations (reaction c). Sodium hydride (60% slurry in mineral oil, 
amount equivalent to 24 mmol) was washed two times under N2 with dry hexane and once with dry 
THF. Then, THF (80 mL) was added and the suspension was cooled in an ice bath. The appropriate 
alcohol (12 mmol) was then dissolved in dry THF (20 mL) and added dropwise to the sodium hydride 
suspension. The mixture was then allowed to reach room temperature. Subsequently, methyl iodide 
(2.25 mL, 36 mmol) was added in one portion and the mixture was stirred overnight at room temp. 
Work-up (Et2O) was followed by column chromatography on silica gel (hexanes-Et2O or hexanes-
EtOAc mixtures) to afford the desired O-methyl ether. 
General procedure for silylations with TBSOTf (reaction d). The appropriate alcohol (4 mmol) was 
dissolved under N2 in dry CH2Cl2 (20 mL) and treated sequentially with 2,6-lutidine (700 L, 6 mmol) 
and TBSOTf (1.15 mL, 5 mmol). The reaction mixture was then stirred for 1 h at room temp. and 
worked up (extraction with CH2Cl2). Column chromatography on silica gel (hexanes-Et2O or hexanes-
EtOAc mixtures) afforded the desired silylated derivative. 
General procedure for acylations with acryloyl chloride (reaction e). The appropriate alcohol (1 
mmol) was dissolved under N2 in dry CH2Cl2 (40 mL), cooled to 78C and treated sequentially with 
ethyl diisopropylamine (2.6 mL, 15 mmol) and acryloyl chloride (800 L, 10 mmol). The reaction 
mixture was stirred for 2 h at 78C and then worked up (extraction with CH2Cl2). Column 
chromatography on silica gel (hexanes-Et2O or hexanes-EtOAc mixtures) afforded the desired ester. 
General procedure for ring-closing metathesis with ruthenium catalyst Ru-I (reaction f). The 
appropriate diolefin (1 mmol) was dissolved under N2 in dry, degassed CH2Cl2 (100 mL) and treated 
with Grubbs first-generation ruthenium catalyst Ru-I (82 mg, 0.1 mmol). The mixture was heated at 
reflux until consumption of the starting material (2-4 h, TLC monitoring!). Solvent removal under 
reduced pressure and column chromatography of the residue on silica gel (hexanes-Et2O or hexanes-
EtOAc mixtures) furnished the desired metathesis product. 
General procedure for acid-catalyzed desilylation (reaction g). The silylated compound (0.6 mmol) 
was dissolved in MeOH (30 mL) and treated with PPTS (30 mg, 0.12 mmol) and water (0.3 mL). The 
mixture was then heated at reflux for 18 h, cooled and neutralized by addition of solid NaHCO3. After 
filtering, the solution was evaporated under reduced pressure, and the oily residue was subjected to 
column chromatography on silica gel (hexanes-EtOAc mixtures). This provided the desired hydroxy 
compound. 
Procedure for O-methylation of compound 4 (Scheme B). See details in page S-13. 
___________________________________________________________________________________ 
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Synthetic schemes 
Scheme A 
 
 
Scheme B 
 
 S-5
Scheme C 
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Synthesis and analytical data of intermediate and final compounds 
 
(R)-Hexadec-1-en-4-ol (16). Prepared in 93% yield from n-tridecanal according to experimental 
conditions a (pag. S-2): oil; []D +2.8 (c 1; CHCl3). Spectral data as reported*. The enantiomeric ratio 
was found to be 90:10 by means of chiral HPLC using a Kromasil 5-AmyCoat column (4.6 x 20 mm). 
Elution was performed with a hexane/isopropanol 99:1 mixture, and a flux of 0.4 mL/min. Elution 
times of both enantiomers: 18.33 (S) and 20.39 min (R). 
* R and S enantiomer: Wetzel, I.; Krauss, J.; Bracher, F.  Lett. Org. Chem. 2012, 9, 169-174. For the R 
enantiomer: []D +4.2 (c 1.9; CH2Cl2) with 99% ee. 
___________________________________________________________________________________ 
 
(R)-4-Methoxyhexadec-1-ene (17). Prepared from 16 in 90% yield according to experimental 
conditions c (pag. S-3): oil; []D +2.8 (c 1; CHCl3); 1H NMR (500 MHz)  ddt, J = 17.5, 
10.5, 7 Hz), 5.10-5.00 (2H, br m), 3.34 (3H, s), 3.20 (1H, quint, J  6 Hz), 2.26 (2H, m), 1.50-1.35 (4H, 
br m), 1.35-1.25 (18H, br m), 0.89 (3H, t, J = 7 Hz); 13C NMR (125 MHz)  135.0, 80.8 (CH), 116.7, 
37.8, 33.4, 31.9, 29.8-29.4 (several overlapped signals), 25.3, 22.7 (CH2), 56.5, 14.1 (CH3); HR ESMS 
m/z (% rel. int.) 277.2512 (M+Na+). Calcd. for C17H34NaO, 277.2507. 
___________________________________________________________________________________ 
 
(4R,6R)-6-Methoxyoctadec-1-en-4-ol (19). Prepared in two steps from 17 (via the non isolated 
aldehyde 18) in 72% overall yield according to experimental conditions +b (pag. S-2). The isolated 
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compound was an 87:13 mixture of diastereoisomers which were very difficult to separate and was 
used as such in the next step. For analytical purposes, an aliquot could be concentrated to about 95% 
purity by means of careful column chromatography: oil; D 18.8 (c 1, CHCl3); IR max 3400 (br, 
OH) cm-1; 1H NMR (500 MHz)  ddt, J = 17, 10.3, 7.2 Hz), 5.15-5.05 (2H, br m), 3.95 (1H, 
m), 3.47 (1H, m), 3.37 (3H, s), 2.80 (1H, br s, OH), 2.24 (2H, m), 1.70-1.40 (4H, br m), 1.35-1.25 
(20H, br m), 0.89 (3H, t, J = 7 Hz); 13C NMR (125 MHz)  135.0, 79.3, 68.0 (CH), 117.5, 42.3, 39.0, 
33.1, 31.9, 29.8-29.4 (several overlapped signals), 25.4, 22.7 (CH2), 56.7, 14.1 (CH3); HR ESMS m/z 
(% rel. int.) 321.2775 (M+Na+). Calcd. for C19H38NaO2, 321.2769. 
___________________________________________________________________________________ 
 
(4R,6R)-4-(Tert-butyldimethylsilyloxy)-6-methoxyoctadec-1-ene (20). Prepared from 19 in 93% 
yield according to experimental conditions d (pag. S-3). Like 19, the isolated 20 was a 87:13 mixture of 
diastereoisomers which were very difficult to separate and was used as such in the next step. For 
analytical purposes, an aliquot could be concentrated to about 95% purity by means of careful column 
chromatography: oil; D 6.8 (c 1, CHCl3); 1H NMR (500 MHz)  ddt, J = 17, 10, 7 Hz), 
5.10-5.05 (2H, br m), 3.93 (1H, m), 3.34 (1H, m), 3.30 (3H, s), 2.24 (2H, m), 1.60-1.40 (4H, br m), 
1.35-1.25 (20H, br m), 0.90 (12H, strong singlet of 9H overlapping a methyl triplet at 0.89 ppm), 0.08 
(6H, s); 13C NMR (125 MHz)  18.1 (C), 134.8, 77.1, 68.7 (CH), 116.9, 42.8, 41.7, 33.1, 31.9, 29.9-
29.4 (several overlapped signals), 24.8, 22.7 (CH2), 55.6, 26.0 (x 3), 14.1, 4.1, 4.7 (CH3). HR ESMS 
m/z (% rel. int.) 413.3816 (M+H+). Calcd. for C25H53O2Si, 413.3815. 
___________________________________________________________________________________ 
 
(4S,6R,8R)-6-(Tert-butyldimethylsilyloxy)-8-methoxyicos-1-en-4-ol (21). Prepared in two steps from 
20 (via a non isolated intermediate aldehyde) in 80% overall yield according to experimental conditions 
b (pag. S-2). The isolated compound was a 72:28 mixture of diastereoisomers which, after careful 
chromatographic purification on silica gel (hexanes-EtOAc 98:2), yielded the major component 21 as a 
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pure compound: oil; []D 3.9 (c 1.3; CHCl3); IR max 3440 (br, OH) cm-1; 1H NMR (500 MHz)  
 ddt, J = 17, 10, 7 Hz), 5.15-5.05 (2H, br m), 4.18 (1H, m), 4.04 (1H, m), 3.50 (1H, br s, OH), 
3.29 (3H, s), 3.25 (1H, m), 2.30-2.15 (2H, br m), 1.75-1.40 (6H, br m), 1.35-1.25 (20H, br m), 0.90 
(9H, s), 0.88 (3H, t, J = 6.8 Hz), 0.13 (3H, s), 0.10 (3H, s); 13C NMR (125 MHz)  17.9 (C), 135.0, 
77.3, 69.3, 68.0 (CH), 117.1, 42.4, 42.1, 41.0, 32.8, 31.9, 29.9-29.4 (several overlapped signals), 24.6, 
22.7 (CH2), 55.6, 25.9 (x 3), 14.1, 4.4, 4.9 (CH3). HR ESMS m/z (% rel. int.) 457.4080 (M+H+). 
Calcd. for C27H57O3Si, 457.4077. 
___________________________________________________________________________________ 
 
(4S,6S,8R)-6-(Tert-butyldimethylsilyloxy)-8-methoxyicos-1-en-4-yl  acrylate (22). Prepared from 21 
in 79% yield according to experimental conditions e (pag. S-3): oil; []D +2.1 (c 1.1; CHCl3); IR max 
1726 (C=O) cm-1; 1H NMR (500 MHz)  6.37 (1H, dd, J = 17.3, 1.5 Hz), 6.10 (1H, dd, J = 17.3, 10.7 
Hz), 5.80 (1H, dd, J = 10.7, 1.5 Hz), 5.76 (1H, ddt, J = 17, 10.2, 7 Hz), 5.10-5.05 (3H, br m), 3.85 (1H, 
m), 3.29 (3H, s), 3.28 (1H, m), 2.45-2.35 (2H, m), 1.85-1.40 (6H, br m), 1.35-1.25 (20H, br m), 0.89 
(12H, strong singlet of 9H overlapping a methyl triplet at 0.89 ppm), 0.05 (3H, s), 0.04 (3H, s); 13C 
NMR (125 MHz)  165.7, 18.0 (C), 133.4, 129.0, 77.5, 71.2, 67.0 (CH), 130.2, 118.0, 42.7, 42.0, 39.0, 
33.2, 31.9, 29.9-29.4 (several overlapped signals), 24.7, 22.7 (CH2), 55.8, 26.0 (x 3), 14.1, 4.3, 4.4 
(CH3); HR ESMS m/z (% rel. int.) 533.4003 (M+Na+). Calcd. for C30H58NaO4Si, 533.4002. 
___________________________________________________________________________________ 
 
(6S)-6-[(2S,4R)-2-(Tert-butyldimethylsilyloxy)-4-methoxyhexadecyl]-5,6-dihydro-2H-pyran-2-one 
(23). Prepared from 22 in 85% yield according to experimental conditions f (pag. S-3): oil; D 5.6 (c 
1.1, CHCl3); IR max 1735 (C=O) cm-1; 1H NMR (500 MHz)  6.87 (1H, dt, J = 9.8, 4 Hz), 6.00 (1H, br 
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d, J = 9.8 Hz), 4.59 (1H, m), 4.07 (1H, m), 3.29 (3H, s), 3.24 (1H, quint, J  6 Hz), 2.35-2.30 (2H, m), 
2.03 (1H, m), 1.65-1.40 (5H, br m), 1.35-1.20 (20H, br m), 0.88 (12H, strong singlet of 9H overlapping 
a methyl triplet at 0.88 ppm), 0.09 (3H, s), 0.07 (3H, s); 13C NMR (125 MHz)  164.2, 18.0 (C), 145.1, 
121.5, 77.7, 74.6, 66.2 (CH), 43.4, 43.3, 33.2, 31.9, 29.9-29.4 (several overlapped signals), 24.7, 22.6 
(CH2), 55.8, 25.9 (x 3), 14.1, 4.4, 4.5 (CH3); HR ESMS m/z (% rel. int.) 505.3696 (M+Na+). Calcd. 
for C28H54NaO4Si, 505.3689. 
___________________________________________________________________________________ 
 
(6S)-6-[(2S,4R)-2-Hydroxy-4-methoxyhexadecyl]-5,6-dihydro-2H-pyran-2-one (4). Prepared from 
23 in 85% yield according to experimental conditions g (pag. S-3): oil; D 13.1 (c 1.1, CHCl3); IR 
max 3440 (br, OH), 1716 (C=O) cm-1; 1H NMR (500 MHz)  6.86 (1H, m), 6.00 (1H, br d, J = 9.7 Hz), 
4.72 (1H, m), 4.22 (1H, m), 3.45 (1H, m), 3.34 (3H, s), 3.15 (1H, br s, OH), 2.45-2.30 (2H, br m), 1.90-
1.40 (6H, br m), 1.35-1.20 (20H, br m), 0.87 (3H, t, J = 6.8 Hz); 13C NMR (125 MHz)  164.4 (C), 
145.2, 121.3, 79.5, 75.1, 64.6 (CH), 42.9, 39.4, 32.8, 31.9, 30.0, 29.7, 29.6, 29.5-29.4 (several 
overlapped signals), 29.3, 25.5, 22.6 (CH2), 56.6, 14.0 (CH3); HR ESMS m/z (% rel. int.) 391.2827 
(M+Na+). Calcd. for C22H40NaO4, 391.2824. 
___________________________________________________________________________________ 
 
(6S)-6-[(2S,4R)-2,4-Dimethoxyhexadecyl]-5,6-dihydro-2H-pyran-2-one (5). A solution of pyrone 4 
(37 mg, 0.1 mmol) and 1,8-bis(N,N-dimethylamino)naphthalene (129 mg, 0.6 mmol) in dry CH2Cl2 (4 
mL) was treated under N2 with trimethyloxonium tetrafluoroborate (89 mg, 0.6 mmol). The mixture 
was then stirred at room temperature for 7 h and quenched by addition of a saturated solution of NaCl. 
Work up (extraction with CH2Cl2) and column chromatography of the residue on silica gel (hexanes-
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EtOAc 7:3) afforded 5 (25 mg, 65%): oil; D 16.3 (c 0.95, CHCl3); IR max 1726 (C=O) cm-1; 1H 
NMR (500 MHz)  6.88 (1H, m), 6.00 (1H, br d, J = 9.7 Hz), 4.65 (1H, m), 3.68 (1H, m), 3.41 (3H, s), 
3.33 (3H, s), 3.30 (1H, m), 2.40-2.30 (2H, br m), 1.96 (1H, m), 1.75-1.40 (5H, br m), 1.35-1.20 (20H, 
br m), 0.88 (3H, t, J = 7 Hz); 13C NMR (125 MHz)  164.4 (C), 145.1, 121.5, 77.8, 74.9, 74.4 (CH), 
41.3, 39.8, 33.5, 31.9, 29.9-29.3 (several overlapped signals), 24.8, 22.7 (CH2), 57.9, 56.2, 14.1 (CH3); 
HR ESMS m/z (% rel. int.) 405.2976 (M+Na+). Calcd. for C23H42NaO4, 405.2980. 
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(S)-1-Phenyl-3-buten-1-ol (24). Prepared by means of asymmetric allylboration of benzaldehyde 
according to the reported procedure:* oil, []D 38.4 (c 1.1; CHCl3). 
*Brown, H. C.; Jadhav, P. K.  J. Am. Chem. Soc. 1983, 105, 2092-2093: []D 44.9 (c 7.38; C6H6). 
___________________________________________________________________________________ 
 
(R)-1-Methoxy-1-phenyl-3-butene (25). Prepared from 24 in 95% yield according to experimental 
conditions c (pag. S-3): Spectral data as reported*. 
* (a) Hermans, B.; Hevesi, L.  J. Org. Chem. 1995, 60, 6141-6147. (b) von Schrader, T.; Woodward, S.  
Eur. J. Org. Chem. 2002, 3833-3836. 
___________________________________________________________________________________ 
 
(1S,3R)-1-Methoxy-1-phenylhex-5-en-3-ol (27). Prepared in two steps from 25 (via the non isolated 
aldehyde 26) in 85% overall yield according to experimental conditions +b (pag. S-2). The isolated 
compound was a 90:10 mixture of diastereoisomers which was separated by means of column 
chromatography on silica gel (hexanes-EtOAc 95:5) to yield 27 as the major compound*: oil; D 77 
(c 1, CHCl3); IR max 3440 (br, OH) cm-1;  1H NMR (500 MHz) 7.40-7.25 (5H, br m) ddt, 
J = 17, 10, 7 Hz), 5.15-5.05 (2H, br m), 4.50 (1H, dd, J = 8.8, 3.5 Hz), 3.95 (1H, m), 3.27 (3H, s), 2.65 
(1H, br s, OH), 2.30-2.20 (2H, m), 1.92 (1H, ddd, J = 14.5, 8.8, 2.8 Hz), 1.77 (1H, ddd, J =14.5, 8.8, 
3.5 Hz); 13C NMR (125 MHz)  141.8 (C), 134.8, 128.5 (x 2), 127.5, 126.3 (x 2), 81.1, 67.6 (CH), 
117.6, 44.4, 42.0 (CH2), 56.7 (CH3); HR ESMS m/z (% rel. int.) 229.1203 (M+Na+). Calcd. for 
C13H18NaO2, 229.1204. 
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* Compound 27 in admixture with its syn diastereoisomer has been previously reported in racemic 
form: Hoffmann, R.; Brückner, R.  Chem. Ber. 1992, 125, 1471-1484. 
___________________________________________________________________________________ 
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(1R,3R)-3-(Tert-butyldimethylsilyloxy)-1-methoxyhex-5-ene (28). Prepared from 27 in 92% yield 
according to experimental conditions d (pag. S-3): oil; D 62.3 (c 1.2, CHCl3); 1H NMR (500 MHz) 
7.40-7.25 (5H, br m) ddt, J = 17, 10, 7 Hz), 5.10-5.00 (2H, br m), 4.34 (1H, dd, J = 10, 2.6 
Hz), 4.09 (1H, m), 3.21 (3H, s), 2.30-2.25 (2H, m), 1.88 (1H, ddd, J = 14, 10, 2.8 Hz), 1.62 (1H, ddd, J 
=14, 9.5, 3 Hz), 0.98 (9H, s), 0.17 (3H, s), 0.13 (3H, s); 13C NMR (125 MHz)  142.8, 18.2 (C), 134.6, 
128.5 (x 2), 127.4, 126.5 (x 2), 80.2, 68.3 (CH), 117.1, 46.2, 42.7 (CH2), 56.4, 26.0 (x 3), 4.1, 4.7 
(CH3). HR ESMS m/z (% rel. int.) 343.2065 (M+Na+). Calcd. for C19H32NaO2Si, 343.2069. 
___________________________________________________________________________________ 
 
(4S,6R,8S)-6-(Tert-butyldimethylsilyloxy)-8-methoxy-8-phenyloct-1-en-4-ol (29). Prepared in two 
steps from 28 (via a non isolated intermediate aldehyde) in 75% overall yield according to 
experimental conditions b (pag. S-2). After careful chromatographic purification on silica gel 
(hexanes-EtOAc 95:5), 29 was isolated as a pure compound: oil; []D 33.7 (c 1.1; CHCl3); IR max 
3500 (br, OH) cm-1; 1H NMR (500 MHz) 7.40-7.25 (5H, br m) ddt, J = 17, 10, 7 Hz), 5.15-
5.05 (2H, br m), 4.30-4.20 (2H, m), 4.00 (1H, m), 3.20 (3H, s), 2.30-2.15 (2H, m), 1.95-1.90 (2H, m), 
1.74 (1H, ddd, J =14, 10.2, 4.4 Hz), 1.61 (1H, ddd, J =14, 4, 2.5 Hz), 0.96 (9H, s), 0.14 (6H, s); 13C 
NMR (125 MHz)  142.1, 18.0 (C), 134.9, 128.5 (x 2), 127.6, 126.5 (x 2), 80.3, 68.8, 68.0 (CH), 117.1, 
45.5, 42.3, 42.1 (CH2), 56.3, 25.9 (x 3), 4.3, 5.0 (CH3). HR ESMS m/z (% rel. int.) 387.2328 
(M+Na+). Calcd. for C21H36NaO3Si, 387.2331. 
___________________________________________________________________________________ 
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(4S,6R,8S)-6-(Tert-butyldimethylsilyloxy)-8-methoxy-8-phenyloct-1-en-4-yl acrylate (30). Prepared 
from 29 in 78% yield according to experimental conditions e (pag. S-3): oil; []D 9.7 (c 1.2; CHCl3); 
IR max 1725 (C=O) cm-1; 1H NMR (500 MHz)  7.40-7.25 (5H, br m)6.35 (1H, dd, J = 17, 1.5 Hz), 
6.08 (1H, dd, J = 17, 10.3 Hz), 5.80-5.70 (2H, m), 5.15-5.00 (3H, br m), 4.24 (1H, dd, J = 8.3, 5 Hz), 
3.87 (1H, m), 3.19 (3H, s), 2.45-2.35 (2H, m), 1.96 (1H, ddd, J =14, 8.5, 5.3 Hz), 1.84 (1H, ddd, J =14, 
8.2, 4.5 Hz), 1.80-1.70 (2H, m), 0.92 (9H), 0.04 (3H, s), 0.00 (3H, s); 13C NMR (125 MHz)  165.6, 
142.3, 18.1 (C), 133.4, 129.0, 128.5 (x 2), 127.6, 126.7 (x 2), 80.5, 71.1, 66.4 (CH), 130.2, 118.0, 46.9, 
41.9, 39.0 (CH2), 56.3, 26.0 (x 3), 4.5, 4.6 (CH3); HR ESMS m/z (% rel. int.) 441.2437 (M+Na+). 
Calcd. for C24H38NaO4Si, 441.2437. 
___________________________________________________________________________________ 
 
(6S)-6-[(2R,4S)-2-(Tert-butyldimethylsilyloxy)-4-methoxy-4-phenylbutyl]-5,6-dihydro-2H-pyran-
2-one (31). Prepared from 30 in 80% yield according to experimental conditions f (pag. S-3): oil; D 
54.9 (c 1, CHCl3); IR max 1713 (C=O) cm-1; 1H NMR (500 MHz)  7.40-7.25 (5H, br m)6.88 (1H, 
dt, J = 9.8, 4.3 Hz), 6.02 (1H, br d, J = 9.8 Hz), 4.59 (1H, m), 4.24 (1H, dd, J = 8.8, 4 Hz), 4.18 (1H, 
m), 3.17 (3H, s), 2.40-2.30 (2H, m), 2.06 (1H, ddd, J = 14, 8.8, 4 Hz), 1.92 (1H, ddd, J = 14, 8.8, 5.5 
Hz), 1.76 (1H, ddd, J = 14, 6.4, 4.4 Hz), 1.67 (1H, ddd, J = 14, 8.8, 4 Hz), 0.91 (9H, s), 0.10 (3H, s), 
0.06 (3H, s); 13C NMR (125 MHz)  164.2, 142.2, 18.0 (C), 145.0, 128.5 (x 2), 127.7, 126.5 (x 2), 
121.5, 80.5, 74.6, 65.7 (CH), 47.5, 43.4, 30.0 (CH2), 56.3, 25.9 (x 3), 4.4, 4.5 (CH3); HR ESMS m/z 
(% rel. int.) 413.2120 (M+Na+). Calcd. for C22H34NaO4Si, 413.2124. 
___________________________________________________________________________________ 
 S-14
 
(6S)-6-[(2R,4S)-2-Hydroxy-4-methoxy-4-phenylbutyl]-5,6-dihydro-2H-pyran-2-one (6). Prepared 
from 31 in 90% yield according to experimental conditions g (pag. S-3): oil; D 119.1 (c 1, CHCl3); 
IR max 3440 (br, OH), 1713 (C=O) cm-1; 1H NMR (500 MHz)  7.40-7.25 (5H, br m)6.88 (1H, dt, J 
= 9.6, 4 Hz), 6.02 (1H, br d, J = 9.6 Hz), 4.73 (1H, m), 4.49 (1H, dd, J = 8.8, 3 Hz), 4.23 (1H, m), 3.23 
(3H, s), 3.00 (1H, br s, OH), 2.45-2.35 (2H, m), 2.00-1.90 (2H, br m), 1.85-1.70 (2H, m); 13C NMR 
(125 MHz)  164.3, 141.4 (C), 145.3, 128.5 (x 2), 127.7, 126.3 (x 2), 121.3, 81.1, 75.2, 64.6 (CH), 
45.1, 42.4, 30.0 (CH2), 56.7 (CH3); HR ESMS m/z (% rel. int.) 299.1260 (M+Na+). Calcd. for 
C16H20NaO4, 299.1259. 
___________________________________________________________________________________ 
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S-2/S-15: NMR spectra of new intermediate and final compounds 
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S-2/S-17: NMR spectra of new intermediate and final compounds 
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S-2/S-13: NMR spectra of new intermediate and final compounds 
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